Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
Haematologica
; 106(12): 3240-3244, 2021 12 01.
Article
in En
| MEDLINE
| ID: mdl-34551506
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quality of Life
/
Leukemia, Myeloid, Acute
Type of study:
Clinical_trials
/
Etiology_studies
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Haematologica
Year:
2021
Document type:
Article